Petros Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on men’s health therapeutics with a full range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It commercializes therapeutics for men's health issues, such as endothelial dysfunction, psychosexual and psychosocial ailments, hormone health, and substance-use disorders. It also commercializes and develops Stendra, a PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also markets its own line of ED products in the form of vacuum erection device products through its subsidiaries, Timm Medical and PTV. In addition to ED products, it has a global license (the Hybrid License) to develop and commercialize H100, a novel and patented topical formulation candidate for the treatment of acute Peyronies disease.